Novartis Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera

Novartis (NYSE: NVS) announced today that five-year treatment with Jakavi® (ruxolitinib) suggested an overall survival advantage for ...